BRAF V600E mutation in early-stage multiple myeloma: Good response to broad acting drugs and no relation to prognosis

Blood Cancer Journal

Volumn 5, Issue 3, 2015, Pages

  Rustad, E H ^a   Dai, H Y ^b   Hov, H ^a,b   Coward, E ^a,c   Beisvag, V ^a   Myklebost, O ^c,d   Hovig, E ^c,d,e   Nakken, S ^c,d   Vodak D ^c,d   Meza Zepeda, L A ^c,d   Sandvik, A K ^a   Wader, K F ^b   Misund, K ^a   Sundan, A ^a   Aarset, H ^b   Waage, A ^a,b,c  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c Norwegian Cancer Genomics Consortium   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; B RAF KINASE; CREATININE; IMMUNOMODULATING AGENT; PROTEASOME INHIBITOR; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; PHARMACOLOGICAL BIOMARKER;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE MYELOMA; MYELOMA CELL; OVERALL SURVIVAL; PHENOTYPE; PREVALENCE; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; ADULT; CANCER STAGING; DISEASE FREE SURVIVAL; EXOME; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; DISEASE-FREE SURVIVAL; EXOME; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84989278732     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.24     Document Type: Article

References (29)

1. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-1284.
2. Ekedahl H, Cirenajwis H, Harbst K, Carneiro A, Nielsen K, Olsson H et al. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Br J Dermatol 2013; 169: 1049-1055.
3. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29: 1239-1246.
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New Engl J Med 2011; 364: 2507-2516.
5. Rosove MH, Peddi PF, Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med 2013; 368: 684-685.
6. Peters S, Michielin O, Zimmermann S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol 2013; 31: e341-e344.
7. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012; 366: 2038-2040.
8. Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J et al. Targeting the BRAF V600E Mutation in Multiple Myeloma. Cancer Discov 2013; 3: 862-869.
9. Bohn OL, Hsu K, Hyman DM, Pignataro DS, Giralt S, Teruya-Feldstein J. BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation. Clin Lymphoma, Myeloma Leuk 2014; 14: e65-e68.
10. Sharman JP, Chmielecki J, Morosini D, Palmer GA, Ross JS, Stephens PJ et al. Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma. Clin Lymphoma Myeloma Leuk 2014; 14: e161-e163.
11. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014; 25: 91-101.
12. Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood 2012; 120: 1077-1086.
13. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012; 120: 1067-1076.
14. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012; 120: 1060-1066.
15. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol 2013; 14: e60-e69.
16. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
17. Blade J, Fernandez de Larrea C, Rosinol L, Cibeira MT, Jimenez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 2011; 29: 3805-3812.
18. Durie BGM, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
19. Misund K, Baranowska KA, Holien T, Rampa C, Klein DC, Borset M et al. A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells. J Biomol Screening 2013; 18: 637-646.
20. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-1303.
21. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature Biotechnol 2013; 31: 213-219.
22. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010; 38: e164.
23. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39(Database issue): D945-D950.
24. UniProt Consortium. Activities at the Universal Protein Resource (UniProt). Nucleic Acids Res 2014; 42(Database issue): D191-D198.
25. Finn RD, Bateman A, Clements J, Coggill P, Eberhardt RY, Eddy SR et al. Pfam: the protein families database. Nucleic Acids Res 2014; 42(Database issue): D222-D230.
26. Liu X, Jian X, Boerwinkle E. dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations. Hum Mutat 2013; 34: E2393-E2402.
27. Sigrist CJ, Cerutti L, de Castro E, Langendijk-Genevaux PS, Bulliard V, Bairoch A et al. PROSITE, a protein domain database for functional characterization and annotation. Nucleic Acids Res 2010; 38(Database issue): D161-D166.
28. Griffith M, Griffith OL, Coffman AC, Weible JV, McMichael JF, Spies NC et al. DGIdb: mining the druggable genome. Nat. Methods 2013; 10: 1209-1210.
29. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-472.